カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の肝性脳症治療薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Hepatic Encephalopathy Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19373）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19373
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：99
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の肝性脳症治療薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

肝性脳症治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の肝性脳症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

肝性脳症治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他

用途別セグメントは次のように区分されます。
・診療所、病院、その他

世界の肝性脳症治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Alfa Wassermann S.p.A、Cosmo Pharmaceuticals S.p.A、Horizon Pharma Plc、KannaLife Sciences, Inc.、Ocera Therapeutics, Inc.、Rebiotix Inc.、Spherium Biomed S.L.、Umecrine Cognition AB

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、肝性脳症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な肝性脳症治療薬メーカーの企業概要、2019年～2022年までの肝性脳症治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な肝性脳症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別肝性脳症治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの肝性脳症治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での肝性脳症治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および肝性脳症治療薬の産業チェーンを掲載しています。
・第13、14、15章では、肝性脳症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 肝性脳症治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他
- 用途別分析（2017年vs2021年vs2028年）：診療所、病院、その他
- 世界の肝性脳症治療薬市場規模・予測
- 世界の肝性脳症治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Alfa Wassermann S.p.A、Cosmo Pharmaceuticals S.p.A、Horizon Pharma Plc、KannaLife Sciences, Inc.、Ocera Therapeutics, Inc.、Rebiotix Inc.、Spherium Biomed S.L.、Umecrine Cognition AB
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他
・用途別分析2017年-2028年：診療所、病院、その他
・肝性脳症治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・肝性脳症治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・肝性脳症治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・肝性脳症治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・肝性脳症治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Hepatic Encephalopathy Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Hepatic Encephalopathy Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Clinic accounting for % of the Hepatic Encephalopathy Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While RBX-2660 segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Hepatic Encephalopathy Drug include Alfa Wassermann S.p.A, Cosmo Pharmaceuticals S.p.A, Horizon Pharma Plc, KannaLife Sciences, Inc., and Ocera Therapeutics, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Hepatic Encephalopathy Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
RBX-2660
KLS-13019
GR-3027
SYNB-1020
Others
Market segment by Application can be divided into
Clinic
Hospital
Others
The key market players for global Hepatic Encephalopathy Drug market are listed below:
Alfa Wassermann S.p.A
Cosmo Pharmaceuticals S.p.A
Horizon Pharma Plc
KannaLife Sciences, Inc.
Ocera Therapeutics, Inc.
Rebiotix Inc.
Spherium Biomed S.L.
Umecrine Cognition AB
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hepatic Encephalopathy Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hepatic Encephalopathy Drug, with price, sales, revenue and global market share of Hepatic Encephalopathy Drug from 2019 to 2022.
Chapter 3, the Hepatic Encephalopathy Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hepatic Encephalopathy Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Hepatic Encephalopathy Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Hepatic Encephalopathy Drug.
Chapter 13, 14, and 15, to describe Hepatic Encephalopathy Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Hepatic Encephalopathy Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hepatic Encephalopathy Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 RBX-2660
1.2.3 KLS-13019
1.2.4 GR-3027
1.2.5 SYNB-1020
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Hepatic Encephalopathy Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Hepatic Encephalopathy Drug Market Size & Forecast
1.4.1 Global Hepatic Encephalopathy Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Hepatic Encephalopathy Drug Sales in Volume (2017-2028)
1.4.3 Global Hepatic Encephalopathy Drug Price (2017-2028)
1.5 Global Hepatic Encephalopathy Drug Production Capacity Analysis
1.5.1 Global Hepatic Encephalopathy Drug Total Production Capacity (2017-2028)
1.5.2 Global Hepatic Encephalopathy Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hepatic Encephalopathy Drug Market Drivers
1.6.2 Hepatic Encephalopathy Drug Market Restraints
1.6.3 Hepatic Encephalopathy Drug Trends Analysis
2 Manufacturers Profiles
2.1 Alfa Wassermann S.p.A
2.1.1 Alfa Wassermann S.p.A Details
2.1.2 Alfa Wassermann S.p.A Major Business
2.1.3 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product and Services
2.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Cosmo Pharmaceuticals S.p.A
2.2.1 Cosmo Pharmaceuticals S.p.A Details
2.2.2 Cosmo Pharmaceuticals S.p.A Major Business
2.2.3 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product and Services
2.2.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Horizon Pharma Plc
2.3.1 Horizon Pharma Plc Details
2.3.2 Horizon Pharma Plc Major Business
2.3.3 Horizon Pharma Plc Hepatic Encephalopathy Drug Product and Services
2.3.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 KannaLife Sciences, Inc.
2.4.1 KannaLife Sciences, Inc. Details
2.4.2 KannaLife Sciences, Inc. Major Business
2.4.3 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product and Services
2.4.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Ocera Therapeutics, Inc.
2.5.1 Ocera Therapeutics, Inc. Details
2.5.2 Ocera Therapeutics, Inc. Major Business
2.5.3 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product and Services
2.5.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Rebiotix Inc.
2.6.1 Rebiotix Inc. Details
2.6.2 Rebiotix Inc. Major Business
2.6.3 Rebiotix Inc. Hepatic Encephalopathy Drug Product and Services
2.6.4 Rebiotix Inc. Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Spherium Biomed S.L.
2.7.1 Spherium Biomed S.L. Details
2.7.2 Spherium Biomed S.L. Major Business
2.7.3 Spherium Biomed S.L. Hepatic Encephalopathy Drug Product and Services
2.7.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Umecrine Cognition AB
2.8.1 Umecrine Cognition AB Details
2.8.2 Umecrine Cognition AB Major Business
2.8.3 Umecrine Cognition AB Hepatic Encephalopathy Drug Product and Services
2.8.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Hepatic Encephalopathy Drug Breakdown Data by Manufacturer
3.1 Global Hepatic Encephalopathy Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Hepatic Encephalopathy Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Hepatic Encephalopathy Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Hepatic Encephalopathy Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Hepatic Encephalopathy Drug Manufacturer Market Share in 2021
3.5 Global Hepatic Encephalopathy Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Hepatic Encephalopathy Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Hepatic Encephalopathy Drug Market Size by Region
4.1.1 Global Hepatic Encephalopathy Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Hepatic Encephalopathy Drug Revenue by Region (2017-2028)
4.2 North America Hepatic Encephalopathy Drug Revenue (2017-2028)
4.3 Europe Hepatic Encephalopathy Drug Revenue (2017-2028)
4.4 Asia-Pacific Hepatic Encephalopathy Drug Revenue (2017-2028)
4.5 South America Hepatic Encephalopathy Drug Revenue (2017-2028)
4.6 Middle East and Africa Hepatic Encephalopathy Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Hepatic Encephalopathy Drug Sales in Volume by Type (2017-2028)
5.2 Global Hepatic Encephalopathy Drug Revenue by Type (2017-2028)
5.3 Global Hepatic Encephalopathy Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Hepatic Encephalopathy Drug Sales in Volume by Application (2017-2028)
6.2 Global Hepatic Encephalopathy Drug Revenue by Application (2017-2028)
6.3 Global Hepatic Encephalopathy Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Hepatic Encephalopathy Drug Sales by Type (2017-2028)
7.2 North America Hepatic Encephalopathy Drug Sales by Application (2017-2028)
7.3 North America Hepatic Encephalopathy Drug Market Size by Country
7.3.1 North America Hepatic Encephalopathy Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Hepatic Encephalopathy Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Hepatic Encephalopathy Drug Sales by Type (2017-2028)
8.2 Europe Hepatic Encephalopathy Drug Sales by Application (2017-2028)
8.3 Europe Hepatic Encephalopathy Drug Market Size by Country
8.3.1 Europe Hepatic Encephalopathy Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Hepatic Encephalopathy Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Hepatic Encephalopathy Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Hepatic Encephalopathy Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Hepatic Encephalopathy Drug Market Size by Region
9.3.1 Asia-Pacific Hepatic Encephalopathy Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Hepatic Encephalopathy Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Hepatic Encephalopathy Drug Sales by Type (2017-2028)
10.2 South America Hepatic Encephalopathy Drug Sales by Application (2017-2028)
10.3 South America Hepatic Encephalopathy Drug Market Size by Country
10.3.1 South America Hepatic Encephalopathy Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Hepatic Encephalopathy Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Hepatic Encephalopathy Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Hepatic Encephalopathy Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Hepatic Encephalopathy Drug Market Size by Country
11.3.1 Middle East & Africa Hepatic Encephalopathy Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Hepatic Encephalopathy Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Hepatic Encephalopathy Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Hepatic Encephalopathy Drug
12.3 Hepatic Encephalopathy Drug Production Process
12.4 Hepatic Encephalopathy Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Hepatic Encephalopathy Drug Typical Distributors
13.3 Hepatic Encephalopathy Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Hepatic Encephalopathy Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Hepatic Encephalopathy Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Alfa Wassermann S.p.A Basic Information, Manufacturing Base and Competitors
Table 4. Alfa Wassermann S.p.A Major Business
Table 5. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product and Services
Table 6. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Cosmo Pharmaceuticals S.p.A Basic Information, Manufacturing Base and Competitors
Table 8. Cosmo Pharmaceuticals S.p.A Major Business
Table 9. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product and Services
Table 10. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Horizon Pharma Plc Basic Information, Manufacturing Base and Competitors
Table 12. Horizon Pharma Plc Major Business
Table 13. Horizon Pharma Plc Hepatic Encephalopathy Drug Product and Services
Table 14. Horizon Pharma Plc Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. KannaLife Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 16. KannaLife Sciences, Inc. Major Business
Table 17. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product and Services
Table 18. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Ocera Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Ocera Therapeutics, Inc. Major Business
Table 21. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product and Services
Table 22. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Rebiotix Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Rebiotix Inc. Major Business
Table 25. Rebiotix Inc. Hepatic Encephalopathy Drug Product and Services
Table 26. Rebiotix Inc. Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Spherium Biomed S.L. Basic Information, Manufacturing Base and Competitors
Table 28. Spherium Biomed S.L. Major Business
Table 29. Spherium Biomed S.L. Hepatic Encephalopathy Drug Product and Services
Table 30. Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Umecrine Cognition AB Basic Information, Manufacturing Base and Competitors
Table 32. Umecrine Cognition AB Major Business
Table 33. Umecrine Cognition AB Hepatic Encephalopathy Drug Product and Services
Table 34. Umecrine Cognition AB Hepatic Encephalopathy Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Global Hepatic Encephalopathy Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
Table 36. Global Hepatic Encephalopathy Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 37. Market Position of Manufacturers in Hepatic Encephalopathy Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 38. Global Hepatic Encephalopathy Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 39. Head Office and Hepatic Encephalopathy Drug Production Site of Key Manufacturer
Table 40. Hepatic Encephalopathy Drug New Entrant and Capacity Expansion Plans
Table 41. Hepatic Encephalopathy Drug Mergers & Acquisitions in the Past Five Years
Table 42. Global Hepatic Encephalopathy Drug Sales by Region (2017-2022) & (K Pcs)
Table 43. Global Hepatic Encephalopathy Drug Sales by Region (2023-2028) & (K Pcs)
Table 44. Global Hepatic Encephalopathy Drug Revenue by Region (2017-2022) & (USD Million)
Table 45. Global Hepatic Encephalopathy Drug Revenue by Region (2023-2028) & (USD Million)
Table 46. Global Hepatic Encephalopathy Drug Sales by Type (2017-2022) & (K Pcs)
Table 47. Global Hepatic Encephalopathy Drug Sales by Type (2023-2028) & (K Pcs)
Table 48. Global Hepatic Encephalopathy Drug Revenue by Type (2017-2022) & (USD Million)
Table 49. Global Hepatic Encephalopathy Drug Revenue by Type (2023-2028) & (USD Million)
Table 50. Global Hepatic Encephalopathy Drug Price by Type (2017-2022) & (USD/Pcs)
Table 51. Global Hepatic Encephalopathy Drug Price by Type (2023-2028) & (USD/Pcs)
Table 52. Global Hepatic Encephalopathy Drug Sales by Application (2017-2022) & (K Pcs)
Table 53. Global Hepatic Encephalopathy Drug Sales by Application (2023-2028) & (K Pcs)
Table 54. Global Hepatic Encephalopathy Drug Revenue by Application (2017-2022) & (USD Million)
Table 55. Global Hepatic Encephalopathy Drug Revenue by Application (2023-2028) & (USD Million)
Table 56. Global Hepatic Encephalopathy Drug Price by Application (2017-2022) & (USD/Pcs)
Table 57. Global Hepatic Encephalopathy Drug Price by Application (2023-2028) & (USD/Pcs)
Table 58. North America Hepatic Encephalopathy Drug Sales by Country (2017-2022) & (K Pcs)
Table 59. North America Hepatic Encephalopathy Drug Sales by Country (2023-2028) & (K Pcs)
Table 60. North America Hepatic Encephalopathy Drug Revenue by Country (2017-2022) & (USD Million)
Table 61. North America Hepatic Encephalopathy Drug Revenue by Country (2023-2028) & (USD Million)
Table 62. North America Hepatic Encephalopathy Drug Sales by Type (2017-2022) & (K Pcs)
Table 63. North America Hepatic Encephalopathy Drug Sales by Type (2023-2028) & (K Pcs)
Table 64. North America Hepatic Encephalopathy Drug Sales by Application (2017-2022) & (K Pcs)
Table 65. North America Hepatic Encephalopathy Drug Sales by Application (2023-2028) & (K Pcs)
Table 66. Europe Hepatic Encephalopathy Drug Sales by Country (2017-2022) & (K Pcs)
Table 67. Europe Hepatic Encephalopathy Drug Sales by Country (2023-2028) & (K Pcs)
Table 68. Europe Hepatic Encephalopathy Drug Revenue by Country (2017-2022) & (USD Million)
Table 69. Europe Hepatic Encephalopathy Drug Revenue by Country (2023-2028) & (USD Million)
Table 70. Europe Hepatic Encephalopathy Drug Sales by Type (2017-2022) & (K Pcs)
Table 71. Europe Hepatic Encephalopathy Drug Sales by Type (2023-2028) & (K Pcs)
Table 72. Europe Hepatic Encephalopathy Drug Sales by Application (2017-2022) & (K Pcs)
Table 73. Europe Hepatic Encephalopathy Drug Sales by Application (2023-2028) & (K Pcs)
Table 74. Asia-Pacific Hepatic Encephalopathy Drug Sales by Region (2017-2022) & (K Pcs)
Table 75. Asia-Pacific Hepatic Encephalopathy Drug Sales by Region (2023-2028) & (K Pcs)
Table 76. Asia-Pacific Hepatic Encephalopathy Drug Revenue by Region (2017-2022) & (USD Million)
Table 77. Asia-Pacific Hepatic Encephalopathy Drug Revenue by Region (2023-2028) & (USD Million)
Table 78. Asia-Pacific Hepatic Encephalopathy Drug Sales by Type (2017-2022) & (K Pcs)
Table 79. Asia-Pacific Hepatic Encephalopathy Drug Sales by Type (2023-2028) & (K Pcs)
Table 80. Asia-Pacific Hepatic Encephalopathy Drug Sales by Application (2017-2022) & (K Pcs)
Table 81. Asia-Pacific Hepatic Encephalopathy Drug Sales by Application (2023-2028) & (K Pcs)
Table 82. South America Hepatic Encephalopathy Drug Sales by Country (2017-2022) & (K Pcs)
Table 83. South America Hepatic Encephalopathy Drug Sales by Country (2023-2028) & (K Pcs)
Table 84. South America Hepatic Encephalopathy Drug Revenue by Country (2017-2022) & (USD Million)
Table 85. South America Hepatic Encephalopathy Drug Revenue by Country (2023-2028) & (USD Million)
Table 86. South America Hepatic Encephalopathy Drug Sales by Type (2017-2022) & (K Pcs)
Table 87. South America Hepatic Encephalopathy Drug Sales by Type (2023-2028) & (K Pcs)
Table 88. South America Hepatic Encephalopathy Drug Sales by Application (2017-2022) & (K Pcs)
Table 89. South America Hepatic Encephalopathy Drug Sales by Application (2023-2028) & (K Pcs)
Table 90. Middle East & Africa Hepatic Encephalopathy Drug Sales by Region (2017-2022) & (K Pcs)
Table 91. Middle East & Africa Hepatic Encephalopathy Drug Sales by Region (2023-2028) & (K Pcs)
Table 92. Middle East & Africa Hepatic Encephalopathy Drug Revenue by Region (2017-2022) & (USD Million)
Table 93. Middle East & Africa Hepatic Encephalopathy Drug Revenue by Region (2023-2028) & (USD Million)
Table 94. Middle East & Africa Hepatic Encephalopathy Drug Sales by Type (2017-2022) & (K Pcs)
Table 95. Middle East & Africa Hepatic Encephalopathy Drug Sales by Type (2023-2028) & (K Pcs)
Table 96. Middle East & Africa Hepatic Encephalopathy Drug Sales by Application (2017-2022) & (K Pcs)
Table 97. Middle East & Africa Hepatic Encephalopathy Drug Sales by Application (2023-2028) & (K Pcs)
Table 98. Hepatic Encephalopathy Drug Raw Material
Table 99. Key Manufacturers of Hepatic Encephalopathy Drug Raw Materials
Table 100. Direct Channel Pros & Cons
Table 101. Indirect Channel Pros & Cons
Table 102. Hepatic Encephalopathy Drug Typical Distributors
Table 103. Hepatic Encephalopathy Drug Typical Customers
List of Figures
Figure 1. Hepatic Encephalopathy Drug Picture
Figure 2. Global Hepatic Encephalopathy Drug Revenue Market Share by Type in 2021
Figure 3. RBX-2660
Figure 4. KLS-13019
Figure 5. GR-3027
Figure 6. SYNB-1020
Figure 7. Others
Figure 8. Global Hepatic Encephalopathy Drug Revenue Market Share by Application in 2021
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Global Hepatic Encephalopathy Drug Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028
Figure 13. Global Hepatic Encephalopathy Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Hepatic Encephalopathy Drug Sales (2017-2028) & (K Pcs)
Figure 15. Global Hepatic Encephalopathy Drug Price (2017-2028) & (USD/Pcs)
Figure 16. Global Hepatic Encephalopathy Drug Production Capacity (2017-2028) & (K Pcs)
Figure 17. Global Hepatic Encephalopathy Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. Hepatic Encephalopathy Drug Market Drivers
Figure 19. Hepatic Encephalopathy Drug Market Restraints
Figure 20. Hepatic Encephalopathy Drug Market Trends
Figure 21. Global Hepatic Encephalopathy Drug Sales Market Share by Manufacturer in 2021
Figure 22. Global Hepatic Encephalopathy Drug Revenue Market Share by Manufacturer in 2021
Figure 23. Hepatic Encephalopathy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 Hepatic Encephalopathy Drug Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 Hepatic Encephalopathy Drug Manufacturer (Revenue) Market Share in 2021
Figure 26. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2017-2028)
Figure 27. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2017-2028)
Figure 28. North America Hepatic Encephalopathy Drug Revenue (2017-2028) & (USD Million)
Figure 29. Europe Hepatic Encephalopathy Drug Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific Hepatic Encephalopathy Drug Revenue (2017-2028) & (USD Million)
Figure 31. South America Hepatic Encephalopathy Drug Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa Hepatic Encephalopathy Drug Revenue (2017-2028) & (USD Million)
Figure 33. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2017-2028)
Figure 34. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2017-2028)
Figure 35. Global Hepatic Encephalopathy Drug Price by Type (2017-2028) & (USD/Pcs)
Figure 36. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2017-2028)
Figure 37. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2017-2028)
Figure 38. Global Hepatic Encephalopathy Drug Price by Application (2017-2028) & (USD/Pcs)
Figure 39. North America Hepatic Encephalopathy Drug Sales Market Share by Type (2017-2028)
Figure 40. North America Hepatic Encephalopathy Drug Sales Market Share by Application (2017-2028)
Figure 41. North America Hepatic Encephalopathy Drug Sales Market Share by Country (2017-2028)
Figure 42. North America Hepatic Encephalopathy Drug Revenue Market Share by Country (2017-2028)
Figure 43. United States Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe Hepatic Encephalopathy Drug Sales Market Share by Type (2017-2028)
Figure 47. Europe Hepatic Encephalopathy Drug Sales Market Share by Application (2017-2028)
Figure 48. Europe Hepatic Encephalopathy Drug Sales Market Share by Country (2017-2028)
Figure 49. Europe Hepatic Encephalopathy Drug Revenue Market Share by Country (2017-2028)
Figure 50. Germany Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Hepatic Encephalopathy Drug Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific Hepatic Encephalopathy Drug Revenue Market Share by Region (2017-2028)
Figure 59. China Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Hepatic Encephalopathy Drug Sales Market Share by Type (2017-2028)
Figure 66. South America Hepatic Encephalopathy Drug Sales Market Share by Application (2017-2028)
Figure 67. South America Hepatic Encephalopathy Drug Sales Market Share by Country (2017-2028)
Figure 68. South America Hepatic Encephalopathy Drug Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa Hepatic Encephalopathy Drug Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa Hepatic Encephalopathy Drug Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa Hepatic Encephalopathy Drug Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa Hepatic Encephalopathy Drug Revenue Market Share by Region (2017-2028)
Figure 75. Turkey Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa Hepatic Encephalopathy Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Drug in 2021
Figure 80. Manufacturing Process Analysis of Hepatic Encephalopathy Drug
Figure 81. Hepatic Encephalopathy Drug Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のゴセレリン薬物市場2022年：市場規模予測（～2028年）
  • 世界の神経線維腫症治療薬市場2022年：市場規模予測（～2028年）
  • 世界のCDK4及び6阻害医薬品市場2022年：市場規模予測（～2028年）
  • 世界のアフリベルセプト薬市場2022年：市場規模予測（～2028年）
  • 世界の軟骨形成術治療薬市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19373 )"世界の肝性脳症治療薬市場2022年：市場規模予測（～2028年）" (英文：Global Hepatic Encephalopathy Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。